Table 1:

Summary of clinical trial methodology

StudyDevice UsedTime since Stroke-Symptom OnsetVesselsIV tPAIA tPA
SWIFT19aSolitaire FR (Covidien, Irvine, California); Merci Retriever (Concentric Medical, Mountain View, California)<8 hrLarge-vessel occlusionContraindicated or failedExcluded
ESCAPE20bAny approved neurothrombectomy device<12 hrLarge-vessel occlusionYesUnspecified
REVASCAT21cSolitaire FR<8 hrAnterior circulation occlusionYesAllowed
EXTEND IA22dSolitaire FR<4.5 hrAnterior circulation occlusionYesUnspecified
DAWN23eTrevo retriever (Stryker, Kalamazoo, Michigan)6–24 hrAnterior circulation occlusionContraindicated or failedExcluded
MR RESCUE24fMerci or Penumbra System (Penumbra, Alameda, California)<8 hrLarge-vessel occlusionYesAllowed
THRACE25gAny approved neurothrombectomy device<5 hrLarge-vessel occlusionYesAllowed
  • Note:—IA indicates intra-arterial.

  • a Solitaire With the Intention For Thrombectomy (SWIFT).

  • b Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke (ESCAPE).

  • c Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours (REVASCAT).

  • d Extending the Time for Thrombolysis in Emergency Neurological Deficits—Intra-Arterial (EXTEND-IA).

  • e Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo (DAWN).

  • f Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE).

  • g Trial and Cost Effectiveness Evaluation of Intra-arterial Thrombectomy in Acute Ischemic Stroke (THRACE).